Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

NCT04531540 | Completed Phase 3 Results FDA Drug

• 1 other identifier: 18156
• Study Type: interventional
• Target: 225
• Locations: 1 country
• Sites: 1

Brief Summary

In this study researcher want to learn more about possible skin reactions such after repeated application of an antifungal cream containing Trolamine. They are especially interested in skin irritations or allergic skin reactions. The study plans to enroll about 225 female or male participants with the age 18 - 79 years. The antifungal test cream will be applied on the back between the shoulder blades of the participants and covered by a special dressing patch. This will be repeated 3 times a week for the first 3 weeks of this study applying the cream on the same area of the back. At each visit the skin will be investigated for redness, dryness and other reactions. After a rest period of two weeks the test cream will be applied on the same skin area as before and on a second new skin area nearby. After 2 and 4 days the two skin areas will again be investigated for redness, dryness and other reactions.

Conditions

Hypersensitivity

Outcome Measures

Primary Outcomes (4)

• Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled Subjects

  Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.

  After 4 weeks

• Allergic Reaction Evaluation According to Erythema Scoring Scale During Challenge Phase - All Enrolled Subjects

  Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.

  After 6 weeks

• Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Evaluable Subjects

  Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.

  After 4 weeks

• Allergic Reaction Evaluation According to Erythema Scoring Scale During Challenge Phase - All Evaluable Subjects

  Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: score 0=No visible erythema; score 0.5=Slight, barely perceptible erythema; score 1=Mild erythema; score 2=Moderate erythema; score 3=Marked erythema; score 4=Severe erythema.

  After 6 weeks

Study Arms (1)

Repeated Insult Patch Test

EXPERIMENTAL

During the Induction Phase, participants received 0.2 g Butenafine HCl 1% covered by an occlusive patch on the upper back skin test site three times a week for a total of 9 applications. Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythemal Scoring Scale and if necessary the Additional Scoring system. After 14 days of Rest Phase, on the first day of Challenge Phase, participants received same procedure on original Induction Phase test site and on a virgin test site. The patches were removed and the sites scored 48 hours after application and scored again at 96 hours after application. The test sites were evaluated using the Induction Phase scoring system.

Drug: Butenafine HCl 1% (BAY1896425)

Interventions

Butenafine HCl 1% (BAY1896425) DRUG

Approximately 0.2 g of cream containing butenafine HCl 1% were applied to the upper back skin.

Also known as: Antifungal Cream V61-044 containing Trolamine

Repeated Insult Patch Test

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must have been aged 18 to 79 years, inclusive;
• Female subjects must have produced a negative urine pregnancy test prior to the initiation and also at the completion of the trial;
• Subjects must have been capable of understanding and following directions.

You may not qualify if:

• Subjects who were in ill health or taking medication, other than birth control, which could influence the purpose, integrity or outcome of the trial;
• Subjects who had any visible skin disease that might be confused with a skin reaction to the test material;
• Subjects who were participating in another clinical trial at this facility or any other facility;
• Subjects who used topical or systemic steroids or antihistamines for at least 7 days prior to trial initiation and during the duration of the trial;
• Subjects who had a history of adverse reactions to adhesive tape, cosmetics, OTC drugs or other personal care products;
• Subjects judged by the PI to be inappropriate for the trial;
• Female subjects who were pregnant as evidenced by a urine pregnancy test, planning to become pregnant, or nursing during the course of the trial.

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Unknown Facility

Fairfield, New Jersey, 07004, United States

Location

Related Links

• Click here to find results for studies related to Bayer Healthcare products.

MeSH Terms

Conditions

Hypersensitivity

Interventions

butenafine

Condition Hierarchy (Ancestors)

Immune System Diseases

Results Point of Contact

• Title: Therapeutic Area Head
• Organization: BAYER

clinical-trials-contact@bayer.com

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2020
• First Posted: August 28, 2020
• Study Start: September 9, 2013
• Primary Completion: October 18, 2013
• Study Completion: October 18, 2013
• Last Updated: November 17, 2020
• Results First Posted: September 25, 2020

Record last verified: 2020-10

Locations

US (1)